- Home
- CING vs ASRT Comparison
CING vs ASRT Comparison
Compare CING & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CING | ASRT |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | 13 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.1M | 76.0M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | CING | ASRT |
|---|---|---|
| Price | $5.60 | $18.04 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $34.50 | $18.00 |
| AVG Volume (30 Days) | ★ 390.7K | 273.5K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.20 | $0.58 |
| 52 Week High | $11.89 | $20.45 |
Technical Indicators
Market Signals| Indicator | CING | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 62.85 |
| Support Level | $5.58 | $0.70 |
| Resistance Level | $6.01 | $20.45 |
| Average True Range (ATR) | 0.48 | 0.38 |
| MACD | 0.01 | -0.30 |
| Stochastic Oscillator | 32.32 | 1.13 |
Price Performance
Historical ComparisonAbout CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.